Back
Pfizer lifts revenue floor after second-quarter beat despite quarterly loss

Pfizer lifts revenue floor after second-quarter beat despite quarterly loss

Legacy and acquired drugs offset the slide in Paxlovid and Comirnaty, letting Pfizer raise its 2026 revenue floor while expanding cost savings targets and keeping profit guidance intact.

Fact Check
Every component of the claim is confirmed by primary business-news coverage. Per CNBC and Reuters, Pfizer beat Q2 2026 estimates and raised the low end (floor) of its full-year revenue guidance from $59.5B to $60.5B while posting a quarterly net loss (~$0.04/share). The loss was driven by acquisition-related charges and a multi-billion-dollar impairment on cancer drug sigvotatug vedotin (plus Oxbryta), matching 'charges tied to acquisitions and a cancer-drug impairment.' Strong Eliquis (+19%) and Padcev sales plus $2.5B in additional cost cuts lifted the outlook, matching the claim precisely.
    Reference: 123
Summary

Pfizer reported second-quarter adjusted earnings of 77 cents a share on $15.03 billion in revenue, beating analyst estimates and prompting the drugmaker to lift the low end of its 2026 sales outlook to $60.5 billion from $59.5 billion while keeping adjusted earnings guidance at $2.80 to $3.00 a share. The non-Covid portfolio posted 18% operational growth, with Eliquis sales rising 19% to $2.43 billion and oncology and rare-disease products such as Padcev, Lorbrena and Vyndaqel also gaining, more than offsetting steep declines in Paxlovid and Comirnaty. GAAP results swung to a $248 million loss, or 4 cents a share, after $4.3 billion in non-cash intangible asset impairments, while Pfizer cut its Covid product revenue forecast to about $4 billion from $5 billion and expanded its cost realignment program to target $9.7 billion in net savings through 2029. The company is also pressing ahead with oncology and GLP-1 obesity bets tied to Seagen, Metsera and Innovent Biologics as CFO Dave Denton prepares to leave on August 15 and Cecile Guegan steps in as interim CFO.

Terms & Concepts
  • operational growth: A measure of business performance that strips out currency moves and certain one-time effects to show underlying sales trends.
  • impairment: An accounting charge that reduces the recorded value of an asset when its expected future returns weaken.
  • GLP-1: A class of medicines that mimics a hormone involved in appetite and blood-sugar control, commonly used in obesity treatment.